Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Reducing unnecessary emergency department visits and hospitalizations in the management of pediatric febrile neutropenia.
Greenmyer, Jacob R. , Galardy, Paul J. , Kalmes, Jessica, Allen‐Rhoades, Wendy , Johnson, Heather, Ferdjallah, Asmaa , Pritchett, Joshua C.

Mayo Clinic

JCO Oncology Practice | October 7, 2025 | Volume: 21 | Issue: 10_suppl | Pages: 345-345

10.1200/op.2025.21.10_suppl.345 Get It

345 Background: Pediatric febrile neutropenia (PFN) requires emergent evaluation due to risk of invasive bacterial infection. In the management of PFN, there are varying, accepted definitions for fever requiring emergency evaluation and neutropenia requiring admission. Problem statement: From September 1, 2022 - May 31, 2023, 15.1% (n = 11/73) of emergency department (ED) visits and 17.1% (n = 6/35) of admissions for PFN at Mayo Clinic Rochester may be considered unnecessary due to patients not meeting updated clinical criteria. Aim: Decrease unnecessary ED visits and hospitalizations for PFN by 50% from 15.1% to 7.5% (for ED visits) and from 17.1% to 8.6% (for hospitalizations) by 02/29/2024 without adversely impacting mortality from invasive bacterial infection. Methods: We used the DMAIC framework for process improvement. Interventions included (1) adoption of a higher fever definition for PFN, (2) adoption of a risk-stratified neutropenia definition for hospital admission, (3) provided electronic fever plans with definitions to all families, (4) re-iterated that parents call on-call provider with any concern for fever, (5) educated pediatric oncology staff on definition and management of fevers in pediatric oncology patients, and (6) educated pediatric emergency department staff on definition and management of fevers in pediatric oncology patients. Interventions were tested with rapid tests of change. Relevant clinical characteristics, variables, and outcomes for all patients from pediatric oncology were tracked for all encounters of pediatric oncology patients presenting to the ED for acute illnesses. Results: At baseline,15.1% (n = 11/73) of ED visits for PFN were considered unnecessary due to patients not meeting clinical criteria for emergency evaluation. Post-interventions, unnecessary ED visits for PFN had decreased to 3.4% (n = 1/32). At baseline, 17.1% (n = 6/35) of hospitalizations were considered unnecessary due to patients not meeting clinical criteria for admission. Post-interventions, 7.7% (n = 2/26) of hospitalizations were considered unnecessary. There were no patient deaths from invasive bacterial infection among this cohort at baseline or after interventions. Conclusions: Multiple interventions including adoption of a higher, accepted fever threshold and risk stratified neutropenia definition for PFN was associated with a reduction of unnecessary ED visits and hospitalizations for PFN without an increase in mortality from invasive bacterial infection. The projected medical expense savings of approximately $144,000-$210,000 per year.
Robotic-Assisted Electromagnetic Guidance Improves Success of Percutaneous Access for Nephrolithotomy: A Study of Novices and Experts
Ballantyne, Christopher, Wymer, Kevin , Sehgel, Nancy L., Chew, Ben H. , Elkhoury, Fuad, Sivalingam, Sri , Dunn, Matthew D. , Borofsky, Michael S. , Humphreys, Mitchell R. , Ballantyne, Christopher C, Chew, Ben H

Mayo Clinic

Journal of Endourology | October 6, 2025 | Volume: 39 | Issue: 8 | Pages: 772-780

10.1177/08927790251368775 | PMID 40792637 Get It

Introduction: Percutaneous nephrolithotomy (PCNL) has been a mainstay treatment for large stone burdens since the 1980s, historically offering improved stone-free rates over retrograde intrarenal surgery (RIRS). Gaining optimal access into the renal collecting system can be challenging, requiring advanced skills or interventional radiology assistance. The learning curve for fluoroscopic and ultrasonography access can be steep, with only a minority of PCNL access performed by urologists in the United States. This study compares robotic-assisted electromagnetic (EM) guidance to traditional fluoroscopy for obtaining percutaneous renal access between cohorts of novice and expert urologists. Methods: Ten novices and five expert urologists used robotic-assisted EM guidance to obtain access in a modified supine position compared with using fluoroscopy in a traditional prone position in human cadavers. Primary success was defined as papillary access. Performance metrics, including number of puncture attempts, time to access, radiation exposure, and participant confidence, were compared between novices and experts. Results: Robotic-assisted EM guidance improved success rates for both novices (100% vs 70%) and experts (93% vs 87%) compared with fluoroscopy. Novices showed greater accuracy using robotic assistance (97% vs 37%). The number of insertion attempts decreased with robotic guidance for both groups (novices: 3.42 ± 0.44 vs 1.47 ± 0.19; experts: 2.13 ± 0.36 vs 1.40 ± 0.24; p < 0.002). EM guidance ( p < 0.05) and experience ( p < 0.05) significantly reduced the time from needle insertion to access (novices: 12.86 ± 2.41 minutes vs 4.49 ± 0.96 minutes; experts: 4.90 ± 1.40 minutes vs 4.09 ± 1.12 minutes). Radiation exposure was notably lower with EM guidance (novices, 1.12 ± 0.17 mGy vs 4.86 ± 0.70 mGy; experts, 0.69 ± 0.12 mGy vs 4.11 ± 1.21 mGy; p < 0.001). Novices felt more confident (5[3–5] vs 2[1–4], p < 0.001) and at ease (5[3–5] vs 2.75[1–3], p < 0.001) with EM guidance. Conclusion: Robotic-assisted EM guidance improves percutaneous access success, reduces attempts and radiation exposure, and enhances novice confidence and accuracy. This technology could enable urologists to more effectively and safely perform PCNL, especially for less experienced practitioners.
P17.34.B BELZUTIFAN IN CLINICAL PRACTICE: OUTCOMES AND SAFETY IN A REAL-WORLD COHORT OF PATIENTS WITH VHL-ASSOCIATED NEOPLASMS
Galloway, Taylor , Schultz, Sydney , Thomsen, Anna, Ruff, Michael W. , Uhm, Joon H. , Carabenciov, Ivan D. , Jones, James E., Caron, Samantha, Iezzi, Raymond , Mrugała, Maciej M. , Porter, A B, Pagliaro, Lance C. , Dronca, Roxana , Pichurin, Pavel N. , Sonbol, Bassam Bassam, Riegert‐Johnson, Douglas L. , Dhamija, Rhadika, Orme, Jacob J. , Halfdanarson, Thor R, Hobday, Timothy J. , Patrick, M., Ser, Merve Hazal , Karbhari, Nishika , Neth, Bryan J. , Lachance, Daniel Honore , Riaz, Irbaz Bin , Borad, Mitesh J. , Patrick, M W, Sener, Uğur

Mayo Clinic

Neuro-Oncology | October 3, 2025 | Volume: 27 | Issue: Supplement_3 | Pages: iii163-iii163

10.1093/neuonc/noaf193.550 Get It

Abstract BACKGROUND Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome characterized by development of multiple neoplasms, including central nervous system (CNS) hemangioblastomas, renal cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNETs), and retinal hemangioblastomas. Belzutifan, a hypoxia-inducible factor 2-alpha (HIF-2α) inhibitor, has demonstrated efficacy in treating VHL-associated tumors. This study evaluates our institutional experience with belzutifan in patients with VHL-related tumors. MATERIAL AND METHODS We conducted a retrospective cohort study across three Mayo Clinic sites, including patients aged ≥18 years with genetically confirmed VHL disease who received belzutifan between October 2021 and March 2025. Clinical/radiological data, and adverse events (AEs) were extracted from electronic health records. Tumor responses were assessed using RECIST v1.1 criteria for RCC, pNET, CNS hemangioblastoma. Retinal hemangioblastoma responses were evaluated through ophthalmologic assessments. RESULTS Forty-five patients were included (median age 44 58% female). Sixty-seven percent had RCC, 91% had CNS hemangioblastomas, 53% had pNETs, and 62% had retinal hemangioblastomas. The median duration of belzutifan therapy was 22.6 months (range 1.0-41.4 months). Among patients with RCC (n=26), overall response rate (ORR) was 19% and median time to best response (MTBR) was 7.4 months. Five patients had partial response (PR), 15 had stable disease (SD), and 1 had progressive disease (PD). For CNS hemangioblastomas (n=41), ORR was 12%, MTBR was 6.2 months. 5 patients had PR, 30 had SD, and none had PD. For pNET (n=17), ORR was 41%, MTBR was 8.2 months. One patient had CR, 6 patients had PR, 6 had SD, none had PD. For retinal hemangioblastomas (n=28), 6 (21%) showed improvement, 9 (32%) remained stable, and 3 (11%) showed progression. MTBR was 6.7 months. Treatment-related AEs occurred in 98% of patients. Common AEs included anemia (89%), fatigue (80%), hypoxia (18%), and headache (13%). Grade 3 AEs were observed in 20% of patients, including anemia (7%), hypoxia (9%), fatigue (4%), pneumonitis (2%), loss of consciousness (2%). One patient experienced a grade 4 event (status epilepticus). Anemia management involved iron supplementation (n=11), RBC transfusion (n=3), dose reduction (n=2), treatment holiday (n=8), permanent discontinuation (n=1). Hypoxia management included dose reduction (n=1), treatment holiday (n=3), discontinuation (n=1). CONCLUSION Belzutifan shows clinical activity across various VHL-associated neoplasms in real-world practice, with a manageable safety profile. The lower ORR compared to the phase III trial may reflect differences in baseline disease, including lower tumor burden in our cohort. These findings support its continued use in VHL disease, with attention to monitoring and managing treatment-related AEs.
Calibration of multisite raters for prospective visual reads of amyloid PET scans
Soleimani‐Meigooni, David N. , Pezzoli, Stefania , Joie, Renaud La , Lin, Zoe, Soppe, Carol L., Koran, Mary Ellen , Villemagne, Victor L. , Windon, Charles , Zeineh, Michael , Biber, Sarah , Kukull, Walter A. , O’Connell, Heather, Peterson, Daniel J. , Mormino, Elizabeth C. , Johnson, Sterling C., Rabinovici, Gil D. , Initiative, Alzheimer's Disease Neuroimaging, Koran, Mary Ellen I. , La Joie, Renaud , Rabinovici, Gil D , Windon, Charles , Zeineh, Michael , Blazhenets, Ganna , Lin, Zoe, Johnson, Derek R. , McConathy, Jonathan , Nasrallah, Ilya M. , Ponisio, Maria Rosana , Tanner, Jeremy A. , O'Connell, Heather, Johnson, Sterling C. , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | October 1, 2025 | Volume: 21 | Issue: 10 | Pages: No page available

10.1002/alz.70732 | PMID 41030129 Get It

Abstract INTRODUCTION In multicenter Alzheimer's disease studies, amyloid positron emission tomography (PET) visual reads are typically performed centrally by a few experts. Incorporating a broader reader network enhances scalability and generalizability. METHODS Ten neuroimaging experts from eight Alzheimer's Disease Research Centers (ADRCs) visually read 180 amyloid PET scans (30 scans and 15 duplicate scans for each of four tracers, imaged across a wide variety of scanners), using preferred reading software without anatomical imaging or quantitation. Scans were classified as elevated or non‐elevated per tracer‐specific criteria. Inter‐ and intra‐rater agreement was assessed. RESULTS Inter‐rater agreement was substantial (Fleiss’ κ = 0.78), with full consensus on 69% of scans. Inter‐rater reliability was substantial to perfect across tracers (Fleiss’ κ = 0.70–0.87). Intra‐rater agreement was substantial to perfect (Cohen's κ = 0.79‐1). Scans with intermediate (10–40 Centiloid) quantitation had lower reader agreement. DISCUSSION A multicenter expert network achieved substantial agreement classifying amyloid PET scans. These scans provide a standard for reader training and reliability assurance in future studies. Highlights Calibration methods ensure reliable amyloid positron emission tomography (PET) visual reads across multiple raters. Substantial agreement is possible across readers using their preferred tools. Agreement is also substantial regardless of the amyloid PET tracer used. Scans with intermediate (10–40 Centiloid) quantitation have lower reader agreement. The calibration set will become a training tool for amyloid PET visual read studies.
Shared environments can facilitate microbial transmission and alter metabolic outcomes
Comba, Işın Y. , Hoops, Suzie , Till, Lisa , Johnson, Stephen , Yang, Xiao , Pera, Kathie Culhane, Pergament, Shannon , Knights, Dan , Kashyap, Purna , Louwies, Tijs, Comba, Isin Y , Vangay, Pajau , Louwies, Tijs

Mayo Clinic

Gut Microbes | October 1, 2025 | Volume: 17 | Issue: 1 | Pages: No page available

10.1080/19490976.2025.2562345 | PMID 41029180 Get It

Abusive Bruising and Cutaneous Mimics Module in the Child Abuse Pediatrics Curriculum for Physicians (CAP-CuP)
Johnson, Katie L. , Brown, Emily , Pierce, Mary Clyde , McCulloch, Danielle, Crumm, Caitlin E. , Brown, Emily C B , Pierce, Mary C , McCulloch, Danielle

Mayo Clinic

MedEdPORTAL | September 30, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11549 | PMID 41036450 Get It

Primary Care Clinician Preferences and Perspectives on Multi-Cancer Detection Testing Across an Integrated Healthcare System
Austin, Jessica D. , Nelson, Ilyse A., Tilburt, Jon C. , Ellinghysen, Eric R., Yee, Claire , Quillen, Jaxon , Dougan, Brian M. , Presutti, John R., Samadder, N. Jewel , Ghosh, Karthik, Ressler, Steven W. , Hurt, Ryan T. , Samadder, Niloy Jewel, Ressler, Steven W , Ghosh, Karthik , Austin, Jessica D , Yee, Claire , Quillen, Jaxon K , Nelson, Ilyse A.

Mayo Clinic

Journal of Personalized Medicine | September 29, 2025 | Volume: 15 | Issue: 10 | Pages: 452

10.3390/jpm15100452 | PMID 41149814 Get It

Background/Objectives: Multi-cancer detection (MCD) tests have emerged as a promising tool to redefine the landscape of early cancer detection. Implementation of this novel technology will likely fall to primary care clinicians (PCC). The purpose of this study is to characterize and explore differences in PCCs perceptions and preferences towards MCD testing. Methods: Between March and May of 2023, this cross-sectional survey was administered to 281 PCCs, including physicians and advanced care providers practicing within an integrated healthcare system spanning five states. The survey collected data on self-reported characteristics, perceptions of MCD testing, and preferences for learning about MCD testing. Analysis was limited to those with no prior experience with MCD testing (N = 181, response rate 22.8%). Descriptive statistics summarized key variables and chi-square tests assessed differences in perceptions and preferences by key characteristics. Results: Most PCCs were interested in MCD testing (66.3%), but limited knowledge/awareness of MCD testing and confidence to manage patients with a positive test were observed, along with concerns around cost (76.7%) and misuse/poor implementation. The primary preferences for learning about MCD testing were online courses or classroom instruction (64.5%). Significant differences in perceptions and preferences for learning were observed by location, degree, and years in practice. Conclusions: PCCs in our study held positive views towards MCD testing, but gaps and variation in knowledge and confidence towards MCD testing and concerns around the cost and misuse/poor implementation were observed. While efforts to train and educate all PCCs on MCD testing is a critical first step, more research is needed to understand how best to support implementation tailored to individual and system-level needs and characteristics.
Abstract A064: Uncoupling CX3CL1-CX3CR1 Axis in IPMN Development Through Transgenic Mouse Models
Li, Ding , Roeck, Kaely, Maeder, E. , Weiskittel, Taylor M. , Rodman, Esther , Maynes, Mark , Johnson, Aaron J. , Sun, Jie , Billadeau, Daniel D. , Maeder, Easton, Zhang, Cheng , Maynes, Mark A , Zhu, Bibo , Johnson, Aaron J. , Sun, Jie , Hu, Li

Mayo Clinic

Cancer Research | September 28, 2025 | Volume: 85 | Issue: 18_Supplement_3 | Pages: A064-A064

10.1158/1538-7445.pancreatic25-a064 Get It

Abstract BACKGROUND Intraductal papillary mucinous neoplasm (IPMN) is one of the two most common precursor lesions leading to the development of pancreatic ductal adenocarcinoma (PDA). IPMNs comprise a heterogeneous group of tumors with a wide range of grades and histotypes, and the emergence of single-cell RNA sequencing (RNA-seq) and multiplex digital spatial profiling have characterized unique cell populations, including dysplastic epithelial and immune cells, within the heterogeneous tumor microenvironment that carry signature gene expressions, which could be used as markers for disease progression. However, it is not clear on the heterogeneity of the epithelial and immune response of the evolution during progression of IPMN to PDA. OBJECTIVE Combining nuclear GSK-3β with oncogenic KRas mice (referred to as KNGC – KRas, nuclear GSK-3β, Cre) resulted in the development of IPMN. We have found that 4-week-old KNGC mice show progressive desmoplasia and ductal lesion development with increased M2-like macrophage infiltration. Interestingly, CX3CL1 (fractalkine), a chemokine involved in the recruitment of CX3CR1-expressing monocytes and M2-like macrophage conversion in various disease models is expressed by IPMN progenitor ductal cells. We aim to investigate expression and contribution of CX3CL1-CX3CL1 axis in the development and progression of IPMN. METHODS We utilized a newly generated CX3CL1-mCherry and well-established CX3CR1-GFP knockin/knockout mouse for crossbreeding with KNGC and KGC (KRas, GNas, Cre) for lineage tracing and function analysis by immunofluorescent staining, flow cytometry and CyTOF. RESULTS Both KNGC- and KGC-3LmCherry/+ mice harbor a large population of CX3CL1-mCherry/EPCAM+ epithelial cells as compared to 3LmCherry/+ and wildtype (WT) control mice. In KNGC and KGC mice, we show that there was a unique population of macrophages (CD45+ CD11b+ Ly6G- F4/80+ Ly6c- ) with significantly higher expression of CX3CR1 (CX3CR1Hi) that was not seen in WT mice. Significantly, Knockout of CX3CR1 in KNGC-3RGFP/GFP animals had a paucity of M2-like macrophages, reduced T regulatory cells (Tregs), substantially reduced desmoplasia and impaired development of IPMN. CONCLUSIONS The study provides important knowledge regarding the role of CX3CL1-CX3CR1 axis in recruitment and generation of M2-like macrophages, and their impact on the initiation of the immune/stroma microenvironment facilitating IPMN development. Further investigations using these models have the potential to identify new biomarkers for risk stratification and therapeutic intervention. Citation Format: Li Ding, Kaely Roeck, Easton Maeder, Cheng Zhang, Taylor Weiskittel, Esther Rodman, Mark Maynes, Bibo Zhu, Aaron Johnson, Jie Sun, Li Hu, Daniel Billadeau. Uncoupling CX3CL1-CX3CR1 Axis in IPMN Development Through Transgenic Mouse Models [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3):Abstract nr A064.
Inhibition of lipolysis in visceral adipose tissue from obese mice and humans prevents impairment of endothelial Kir2.1 channels
Hudgins, Emma C. , Johnson, Erica J. , Rokka, Sabita, Kashyap, Bhaswati , Mahugu, Arielle, Nguyen, Thanh, Tascone, Anthony R., McCarthy, Elizabeth , Halbert, Caitlin , Fancher, Ibra S.

Mayo Clinic

Channels | September 25, 2025 | Volume: 19 | Issue: 1 | Pages: No page available

10.1080/19336950.2025.2564651 | PMID 40996861 Get It

Pediatric Heart Failure: A Practical Guide for Primary Care Providers Supporting Families Across the Care Continuum
Amdani, Shahnawaz , Puri, Kriti , Glickstein, Julie S. , Johnson, Jonathan N. , Harahsheh, Ashraf S. , Makhoul, Majd , Denfield, Susan W. , Glickstein, Julie , Harahsheh, Ashraf S , Makhoul, Majd , Spinner, Joseph A.

Mayo Clinic

Children | September 25, 2025 | Volume: 12 | Issue: 10 | Pages: 1293

10.3390/children12101293 | PMID 41153476 Get It

Background/Objectives: Pediatric heart failure (HF) is a complex clinical syndrome with diverse etiologies and presentations. Primary care providers (PCPs) are critical in early recognition, family education, and coordination of ongoing care in collaboration with pediatric cardiologists. This review provides a comprehensive guide for PCPs to understand the causes, symptoms, treatments, and longitudinal considerations for children with HF. Methods: We conducted a narrative review synthesizing published evidence and expert consensus guidelines, focusing on the clinical presentation, treatment options, and longitudinal care strategies in children with HF. Results: HF in children most commonly results from congenital heart disease and cardiomyopathy, but includes a wide range of etiologies. Presenting symptoms differ by age, with subtle signs often mistaken for common pediatric illnesses. Treatments range from disease-modifying medications to surgical and transplant therapies. Psychosocial support, mental health, and family-centered care are critical components of long-term management. Conclusions: PCPs are essential partners in the care of children with HF. A proactive, collaborative, and informed approach can improve quality of life, reduce hospitalizations, and support families navigating this challenging diagnosis.